Login to Your Account



European Society for Medical Oncology

Genentech's T-DM1 Phase III: Stronger Still in Breast Cancer

By Randy Osborne
BioWorld Today Contributing Writer

Tuesday, October 2, 2012
With added, positive Phase III breast cancer data from a trial called EMILIA for the antibody-drug conjugate T-DM1, Roche AG subsidiary Genentech Inc. and partner ImmunoGen Inc. uplifted – but didn't overly surprise – investors, who are waiting to see whether the first label permits front-line use in metastatic disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription